SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2002
ENZON, INC
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-2372868
(State or Other (Commission (IRS Employer
Jurisdiction of File Number) Identification No.)
Incorporation)
685 Route 202/206, Bridgewater, New Jersey 08807
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (732) 980-4500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On November 22, 2002, Enzon, Inc. announced the completion of its
acquisition of the North American rights to ABELCET(R) (Amphotericin B Lipid
Complex Injection) from Elan Corporation, plc. A copy of the press release dated
November 22, 2002 announcing the completion of the transaction is attached
hereto as Exhibit 99.1. Such Exhibit is incorporated by reference into this Item
5 and the foregoing statement is qualified in its entirety by reference to such
Exhibit.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
Exhibit Number Description
-------------- -----------
99.1 - Press Release, dated as of November 22, 2002
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENZON, INC.
Date: November 22, 2002 By:________________________________
Kenneth J. Zuerblis
Vice President, Finance and
Chief Financial Officer